Last updated: August 1, 2026
Subutex is the buprenorphine hydrochloride sublingual tablet formerly marketed for opioid use disorder. Its U.S. brand market has ended, and the product has no meaningful remaining exclusivity. Generic buprenorphine sublingual tablets compete primarily on price, supply reliability, dosage strength, and managed-care access. Current clinical development is concentrated on newer buprenorphine delivery systems, including extended-release injections, implants, and alternative formulations, rather than the Subutex tablet itself.
What is Subutex and what is its FDA status?
Subutex contains buprenorphine hydrochloride, a partial mu-opioid receptor agonist and kappa-opioid receptor antagonist used in medication-assisted treatment for opioid use disorder.
| Attribute |
Subutex |
| Active ingredient |
Buprenorphine hydrochloride |
| Dosage form |
Sublingual tablet |
| U.S. indication |
Opioid dependence, now generally described as opioid use disorder |
| Original U.S. sponsor |
Reckitt Benckiser Pharmaceuticals |
| FDA application |
NDA 020732 |
| U.S. approval |
2002 |
| Brand status |
Discontinued from U.S. commercial distribution |
| Generic status |
Multiple generic buprenorphine sublingual tablets |
| Controlled-substance classification |
Schedule III in the United States |
| Principal competing products |
Generic buprenorphine tablets, Suboxone, Zubsolv, Bunavail, Sublocade, Probuphine |
The FDA lists Subutex as a discontinued product. The discontinuation was not classified as a withdrawal from sale for safety or efficacy reasons. Generic buprenorphine sublingual tablets remain FDA-approved and are therapeutically substitutable under applicable state and payer rules. [1]
Subutex is distinct from Suboxone, which combines buprenorphine and naloxone. The buprenorphine-only formulation continues to have clinical relevance for selected patients, including some pregnant patients and individuals who cannot tolerate naloxone-containing products.
What clinical trials are evaluating buprenorphine, and are any studying Subutex directly?
Most current trials evaluate buprenorphine as an active ingredient or treatment strategy rather than the discontinued Subutex brand.
Clinical research through June 2024 has focused on:
- Extended-release injectable buprenorphine for opioid use disorder.
- Low-dose or “microinduction” initiation protocols.
- Buprenorphine treatment during pregnancy and the postpartum period.
- Buprenorphine for adolescents and young adults.
- Transition from fentanyl exposure to buprenorphine.
- Emergency-department initiation and linkage to outpatient care.
- Buprenorphine for chronic pain and opioid tapering.
- Comparative outcomes between buprenorphine and methadone.
- Diversion-resistant and longer-duration delivery systems.
What is the clinical-trial outlook for Subutex tablets?
Subutex itself has a low probability of generating a new branded clinical-development program. The tablet is an established generic dosage form with extensive clinical experience, and sponsors generally have limited commercial incentive to repeat large efficacy trials for the original product.
The relevant clinical evidence base is instead expanding around the buprenorphine molecule and newer delivery systems. Trials involving sublingual buprenorphine may use a generic product, an investigator-specified formulation, or Suboxone rather than the Subutex brand.
Which buprenorphine products have the strongest clinical-development activity?
Sublocade, an extended-release buprenorphine injection marketed by Indivior, has been the principal branded product with continuing commercial and clinical-development activity in the United States. Brixadi, another extended-release buprenorphine injection, was approved by the FDA in 2023 and is marketed by Braeburn. These products compete on monthly or weekly administration, adherence, diversion control, and treatment-site economics rather than tablet price.
The clinical distinction is material:
| Product type |
Administration |
Main commercial advantage |
Main limitation |
| Generic Subutex-equivalent tablet |
Daily sublingual |
Low acquisition cost and flexible dosing |
Adherence, diversion and daily handling |
| Suboxone generic or brand |
Daily sublingual or film |
Broad familiarity and naloxone combination |
Taste, administration burden, naloxone intolerance in selected patients |
| Sublocade |
Monthly injection |
Adherence and reduced diversion |
Higher cost, injection-site administration |
| Brixadi |
Weekly or monthly injection |
Dosing flexibility and long-acting treatment |
Higher cost and site-of-care requirements |
| Probuphine |
Six-month implant |
Long duration |
Limited use, procedural insertion and commercial constraints |
When did Subutex lose market exclusivity?
Subutex lost practical market exclusivity when generic buprenorphine sublingual tablets entered the U.S. market. The key commercial protection was not a currently enforceable Subutex patent position but FDA regulatory exclusivity and product-specific market adoption.
The FDA approved generic buprenorphine sublingual tablets in multiple strengths after the original product’s exclusivity period. Generic competition removed the economic basis for continued broad brand promotion.
What patents protect Subutex?
Subutex does not have a commercially meaningful, live U.S. patent estate comparable to newer long-acting buprenorphine products.
The active ingredient, buprenorphine, was discovered and patented decades before Subutex’s 2002 U.S. approval. Those foundational composition claims expired long ago. Product-specific protection for the sublingual tablet has also ceased to provide a meaningful barrier to generic entry.
The more relevant patent estates have historically involved:
- Buprenorphine-naloxone combinations.
- Sublingual films.
- Long-acting injectable delivery systems.
- Implantable delivery systems.
- Depot formulations and drug-release technologies.
- Manufacturing and device components.
These rights generally protect competing or successor products rather than the discontinued Subutex tablet.
What is the Orange Book status of Subutex?
The FDA Orange Book identifies Subutex under NDA 020732 as a discontinued product. Discontinued status does not mean the FDA revoked the approval. It indicates that the product is no longer marketed by the NDA holder.
The Orange Book remains relevant for determining:
- Whether the branded product is listed as marketed or discontinued.
- Whether listed patents remain associated with the product.
- Whether generic applicants filed ANDAs against the product.
- Whether a reference-listed drug remains available for substitution and regulatory reference.
For commercial purposes, generic buprenorphine tablets now represent the active tablet market. Subutex has limited value as a branded reference product except in historical regulatory, litigation, and clinical comparisons.
Are there Paragraph IV challenges involving Subutex?
Paragraph IV litigation risk for the original Subutex tablet is largely historical because generic products are already approved and marketed.
A Paragraph IV certification is relevant when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed. Once the relevant patents expire or cease to provide an effective barrier, subsequent competition proceeds without a meaningful branded launch-risk event.
The more important patent disputes in buprenorphine have involved:
- Suboxone sublingual film patents.
- Evergreening allegations involving formulation and delivery changes.
- Patent settlements affecting generic buprenorphine-naloxone film entry.
- Long-acting injectable products.
- Device and depot-delivery technologies.
Subutex-equivalent generic tablets do not present the same litigation exposure as branded Suboxone film or long-acting injectable products.
What formulation patents protect buprenorphine products?
Formulation patents are more commercially important than the original Subutex tablet patent position.
Sublingual tablets
Generic tablets generally have low formulation differentiation. Relevant technical attributes include tablet disintegration, dissolution, flavor, excipients, dose uniformity, and stability. These features can support regulatory equivalence and manufacturing quality but rarely create durable commercial protection after basic formulation claims expire.
Sublingual films
Suboxone and competing products have generated patent disputes involving film composition, polymer matrices, dosage uniformity, manufacturing processes, and protection against abuse or misuse. These patents can delay or shape generic entry even when the underlying buprenorphine molecule is long off-patent.
Extended-release injections
Sublocade and Brixadi rely on drug-delivery systems that may be protected by patents directed to:
- Depot-forming polymers.
- Particle size and drug loading.
- Injection volume.
- Release kinetics.
- Administration methods.
- Prefilled syringes and delivery devices.
- Treatment regimens and dosing intervals.
These patents create a more substantial barrier than the legacy Subutex tablet estate because a competing product must reproduce a controlled-release profile, manufacturing process, and clinical-use profile.
How does Subutex compare with Suboxone, Sublocade and Brixadi?
| Factor |
Subutex-equivalent generic |
Suboxone |
Sublocade |
Brixadi |
| Active ingredient |
Buprenorphine |
Buprenorphine/naloxone |
Buprenorphine |
Buprenorphine |
| Delivery |
Sublingual tablet |
Film or tablet |
Monthly injection |
Weekly or monthly injection |
| U.S. brand status |
Brand discontinued |
Brand and generic competition |
Active brand |
Active brand |
| Price position |
Lowest |
Low to moderate depending on product |
Premium |
Premium |
| Diversion risk |
Higher than depot products |
Higher than depot products |
Lower |
Lower |
| Adherence burden |
Daily |
Daily |
Monthly |
Weekly or monthly |
| Patent exposure |
Minimal |
Formulation and film disputes |
Depot and device patents |
Depot and device patents |
| Main buyers |
Pharmacies, Medicaid, clinics |
Pharmacies and clinics |
Treatment providers and payers |
Treatment providers and payers |
Subutex-equivalent tablets remain relevant where low cost, flexible titration, and pharmacy access are priorities. Long-acting injections have stronger pricing power but face reimbursement restrictions, administration requirements, and competition between depot products.
What is the market outlook for Subutex and generic buprenorphine?
The generic Subutex-equivalent market is mature. Unit demand is supported by the continuing opioid-use-disorder treatment market, but revenue growth is constrained by generic pricing.
Market drivers
- High prevalence of opioid use disorder.
- Expanded buprenorphine treatment capacity.
- Emergency-department initiation programs.
- Medicaid and public-health procurement.
- Fentanyl-related treatment demand.
- Broader use by primary-care and behavioral-health providers.
- Reduced federal barriers to prescribing after elimination of the federal X-waiver requirement in 2023.
Market constraints
- Generic price erosion.
- Pharmacy stocking limitations.
- Controlled-substance diversion concerns.
- Reimbursement pressure.
- Competition from methadone and long-acting injections.
- Treatment discontinuation and poor retention.
- State-level differences in prescribing and dispensing practices.
The U.S. Medication Access and Training Expansion provisions in the Consolidated Appropriations Act, 2023 removed the federal DATA-Waiver requirement for prescribing buprenorphine, although prescriber registration and controlled-substance obligations continue. [2]
The market is likely to divide into two segments:
- A high-volume, low-margin generic oral segment.
- A lower-volume, higher-revenue long-acting segment led by depot injections.
Subutex itself is unlikely to regain a branded market position absent a new formulation, delivery system, or commercial relaunch. Generic buprenorphine tablets should retain durable demand, but revenue growth is more likely to track treatment volume than price expansion.
What revenue exposure does Subutex create for manufacturers?
Direct revenue exposure to the Subutex brand is limited because the U.S. brand has been discontinued. Commercial exposure remains through generic buprenorphine tablets and through branded products that use buprenorphine in differentiated delivery systems.
| Exposure area |
Revenue outlook |
| Branded Subutex tablets |
Negligible in the U.S. |
| Generic buprenorphine tablets |
Stable volume, persistent price pressure |
| Buprenorphine-naloxone films |
Competitive and litigation-sensitive |
| Monthly injectable buprenorphine |
Higher revenue per patient, payer-dependent |
| Weekly injectable buprenorphine |
Growth opportunity, reimbursement-sensitive |
| International buprenorphine tablets |
Country-specific, generally mature |
Indivior’s financial exposure is concentrated in Sublocade and other opioid-use-disorder products rather than Subutex. Braeburn’s commercial exposure is tied to Brixadi and related long-acting buprenorphine products. Generic manufacturers compete through abbreviated new drug applications, manufacturing scale, supply continuity, and wholesaler access.
What generic launch scenarios exist for Subutex-equivalent products?
The original generic launch scenario has already occurred. Future competition will be incremental rather than transformational.
Base case
Generic buprenorphine tablets maintain broad availability, with modest volume growth and continued price compression. The product remains important in Medicaid, public programs, and outpatient addiction-treatment settings.
Upside case
Treatment expansion, fentanyl-related demand, and improved primary-care prescribing increase tablet volumes. Long-acting products also expand, but oral buprenorphine remains the lower-cost initiation and maintenance option.
Downside case
Payers shift a larger share of patients toward long-acting injections, generic manufacturers reduce supply because of low margins, or pharmacy restrictions limit dispensing. Tablet demand remains clinically necessary but becomes more concentrated among selected patient populations.
What geographic markets still use Subutex?
Buprenorphine-only tablets remain available in some non-U.S. markets under local brand or generic names. Regulatory treatment varies by country, including:
- Prescription controls.
- Approved indications.
- Pregnancy labeling.
- Availability of buprenorphine-naloxone combinations.
- Reimbursement.
- Pharmacy dispensing rules.
- Use in opioid dependence versus pain.
The U.S. market is the most commercially important reference point for patent and generic analysis, but international market value depends on local registration and reimbursement rather than U.S. Orange Book status.
How strong is the Subutex patent estate?
The Subutex tablet patent estate is weak for exclusivity purposes.
| Patent-estate factor |
Assessment |
| Active ingredient protection |
Expired |
| Original tablet protection |
No meaningful current barrier |
| Generic substitution |
Established |
| Paragraph IV exposure |
Primarily historical |
| Formulation differentiation |
Limited for the legacy tablet |
| Manufacturing barriers |
Moderate quality and controlled-substance requirements |
| Long-acting product barriers |
Material for depot competitors |
| Brand relaunch potential |
Low without new technology |
The principal barriers in this market are regulatory compliance, controlled-substance manufacturing, supply reliability, clinical adoption, and payer access. They are not legacy Subutex patents.
What litigation and settlement issues affect buprenorphine?
Subutex-related litigation is less commercially significant than litigation concerning Suboxone and long-acting buprenorphine products.
Historical legal issues in the broader buprenorphine market have included:
- Patent validity and enforceability.
- Product switching from tablets to films.
- Antitrust claims concerning generic-delay strategies.
- Patent settlements involving generic buprenorphine-naloxone products.
- Orange Book listing practices.
- Formulation and manufacturing patents.
- Product-liability claims involving dental adverse effects associated with transmucosal buprenorphine.
The U.S. FDA updated labeling for transmucosal buprenorphine products to address dental adverse events, including tooth decay, cavities, oral infections, and tooth loss. The agency advised patients and clinicians on oral rinsing and dental follow-up after administration. [3]
Key Takeaways
- Subutex is the discontinued brand of buprenorphine hydrochloride sublingual tablets.
- Generic buprenorphine tablets are the active successor market in the United States.
- Subutex has no meaningful remaining U.S. exclusivity or patent barrier.
- Current clinical development is focused on buprenorphine delivery systems, especially Sublocade and Brixadi.
- Generic oral buprenorphine should retain durable demand but face ongoing price erosion.
- Long-acting injections have stronger formulation and device patent positions than Subutex-equivalent tablets.
- The highest-value commercial opportunities are in adherence-focused delivery systems, not legacy sublingual tablets.
- Buprenorphine prescribing access expanded after the federal X-waiver requirement was eliminated in 2023.
- Subutex-specific Paragraph IV risk is primarily historical.
- The principal market risks are reimbursement, generic supply, diversion controls, and competition from depot injections.
FAQs
Is Subutex still available in the United States?
The Subutex brand is discontinued in the United States, but generic buprenorphine hydrochloride sublingual tablets remain available.
Is generic buprenorphine the same as Subutex?
Generic buprenorphine sublingual tablets contain the same active ingredient and are approved through FDA abbreviated applications. Inactive ingredients, tablet design, labeling, and manufacturer may differ.
Can Subutex be used during pregnancy?
Buprenorphine-only treatment may be selected during pregnancy based on patient-specific clinical judgment. Treatment choice should follow current clinical guidance and individual risk assessment.
Will Subutex face new generic competition?
The original generic market is already established. Future competition is likely to involve additional manufacturers, strengths, and supply contracts rather than a single major patent-expiry event.
Which buprenorphine product has the strongest commercial patent protection?
Long-acting injectable products generally have stronger current patent and technology barriers than generic sublingual tablets. Their protection may cover depot formulations, release kinetics, manufacturing processes, dosing regimens, and delivery devices.
References
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, Subutex, NDA 020732. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Congress. (2022). Consolidated Appropriations Act, 2023, Division FF, Title IV. https://www.congress.gov/117/plaws/publ328/PLAW-117publ328.pdf
-
U.S. Food and Drug Administration. (2022). FDA warns about dental problems with buprenorphine medicines dissolved in the mouth to treat opioid use disorder. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-dental-problems-buprenorphine-medicines-dissolved-mouth-treat-opioid-use
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
National Institute on Drug Abuse. (2024). Medications for opioid use disorder. https://nida.nih.gov/research-topics/medications-to-treat-opioid-addiction
-
Substance Abuse and Mental Health Services Administration. (2023). Buprenorphine quick start guide. https://www.samhsa.gov/sites/default/files/quick-start-guide.pdf
